Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LILAC
2023-503224-66-00Phase 3Authorised
- Sponsor
- Anthos Therapeutics
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) and atrial flutter (AFL) comparing Abelacimab with Placebo (2 arms). Primary endpoints: Time to first confirmed ischemic stroke or systemic embolism, Time to first adjudicated BARC type 3c/5 bleeding and 1 more. Planned start Oct 2023; status: authorised.
02
Drugs
abelacimab
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on 2023-503224-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503224-66-00.